NSI-189 Phase 1b results are likely to be released in Q1. Seems likely that a partnering for NSI-189 (should it happen) would occur after that, possibly in Q2. CUR's NSI -189 is very interesting (being labeled an anti-depressant, but might have value in traumatic brain injury and/or Alzheimer's), sometimes gets overlooked.
it's practically impossible to go thru February 2013 without a PR on either potential partner - and/or
FDA approval on a Phase II trial for ALS................at least one of the three should hit, imho, maybe